Eli Lilly CFO Anat Ashkenazi resigns; Gordon Brooks interim CFO from July 15

ELI LILLY & Co

Anat Ashkenazi resigned as EVP and CFO to pursue opportunity outside pharma; stays through July for transition.
Gordon Brooks, group VP controller and corporate strategy, named interim CFO effective July 15, 2024.
Brooks has 29-year Lilly career including CFO of U.S. Bio-Medicines and chief procurement officer.
No arrangements or family relationships; selection not pursuant to any agreement with outsiders.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed (interim)

Gordon Brooks

interim chief financial officer

LLY · ELI LILLY & Co

Effective: 2024-07-15
Filed: July 10, 2024, 7:59 PM ET

Effective July 15, 2024, Gordon Brooks, age 55, group vice president, controller and corporate strategy, of the Company, will assume the role of interim chief financial officer of the Company.

Departed

Anat Ashkenazi

executive vice president and chief financial officer

LLY · ELI LILLY & Co

Successor: Gordon Brooks
Filed: July 10, 2024, 7:59 PM ET

On June 5, 2024, Eli Lilly and Company (the “Company”) announced that Anat Ashkenazi resigned as executive vice president and chief financial officer of the Company to pursue another career opportunity outside of the pharmaceutical industry.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Gordon Brooks was appointed as interim chief financial officer at ELI LILLY & Co.

Action: appointed
Role: interim chief financial officer

Exact text from the filing

Effective July 15, 2024, Gordon Brooks, age 55, group vice president, controller and corporate strategy, of the Company, will assume the role of interim chief financial officer of the Company.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Anat Ashkenazi resigned as executive vice president and chief financial officer at ELI LILLY & Co.

Action: resigned
Role: executive vice president and chief financial officer

Exact text from the filing

On June 5, 2024, Eli Lilly and Company (the “Company”) announced that Anat Ashkenazi resigned as executive vice president and chief financial officer of the Company to pursue another career opportunity outside of the pharmaceutical industry.

View on SEC.gov

ELI LILLY & Co filing history →

Source: SEC EDGAR

accession 0000059478-24-000164

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.